| 1  | H.728   |
|----|---|
| 2  | Introduced by Representative Houghton of Essex                                  |
| 3  | Referred to Committee on  |
| 4  | Date:   |
| 5  | Subject: Health; Department of Vermont Health Access; Vermont Health            |
| 6  | Benefit Exchange; Medicaid  |
| 7  | Statement of purpose of bill as introduced: This bill proposes to eliminate the |
| 8  | duty of the Vermont Health Benefit Exchange to collect Exchange plan            |
| 9  | premium payments. It would also consolidate the Department of Vermont           |
| 10 | Health Access's prescription drug program reporting requirements, remove a      |
| 11 | requirement that the Department report proposed changes to the Medicaid         |
| 12 | preferred drug list or the Department's drug utilization review procedures to   |
| 13 | the General Assembly prior to implementation, and eliminate a requirement       |
| 14 | that the Department submit proposed rules on its pharmaceutical assistance      |
| 15 | programs to a legislative committee for review and advice.                      |
|    |   |
| 16 | An act relating to the miscellaneous changes affecting the duties of the        |
| 17 | Department of Vermont Health Access   |

| 1  | It is hereby enacted by the General Assembly of the State of Vermont:         |
|----|---|
| 2  | Sec. 1. EXCHANGE PLAN PREMIUM PROCESSING; PURPOSE                             |
| 3  | The purpose of Sec. 2 of this act, which amends 33 V.S.A. § 1805, is to       |
| 4  | transfer the Exchange plan premium processing functions from the Vermont      |
| 5  | Health Benefit Exchange to the insurance carriers as contemplated by 2018     |
| 6  | (Sp. Sess.) Acts and Resolves No. 11, Sec. C.102(a)(3).                       |
| 7  | Sec. 2. 33 V.S.A. § 1805 is amended to read:                                  |
| 8  | § 1805. DUTIES AND RESPONSIBILITIES   |
| 9  | The Vermont Health Benefit Exchange shall have the following duties and       |
| 10 | responsibilities consistent with the Affordable Care Act:                     |
| 11 | * * *   |
| 12 | (C) collecting premium payments made for qualified health benefit             |
| 13 | plans from employers and individuals on a pretax basis, including collecting  |
| 14 | premium payments from multiple employers of one individual for a single plan  |
| 15 | covering that individual; and   |
| 16 | (D)(C) creating a simplified and uniform system for the                       |
| 17 | administration of health benefits.  |
| 18 | * * *   |
| 19 | (6) Determining enrollee premiums and subsidies as required by the            |
| 20 | Secretary of the U.S. Department of the Treasury or of the U.S. Department of |
| 21 | Health and Human Services and informing consumers of eligibility for          |

21

| 1  | premiums and subsidies, including by providing an electronic calculator to        |
|----|---|
| 2  | determine the actual cost of coverage after application of any premium tax        |
| 3  | credit under Section 36B of the Internal Revenue Code of 1986 and any cost-       |
| 4  | sharing reduction under Section 1402 of the Affordable Care Act.                  |
| 5  | Sec. 3. 33 V.S.A. § 2001 is amended to read:                                      |
| 6  | § 2001. LEGISLATIVE OVERSIGHT   |
| 7  | (a) In connection with the Pharmacy Best Practices and Cost Control               |
| 8  | Program, the Commissioner of Vermont Health Access shall report for review        |
| 9  | by the House Committees on Appropriations, on Health Care, and on Human           |
| 10 | Services and the Senate Committees on Appropriations and on Health and            |
| 11 | Welfare prior to any modifications:   |
| 12 | (1) the compilation that constitutes the preferred drug list or list of drugs     |
| 13 | subject to prior authorization or any other utilization review procedures;        |
| 14 | (2) any utilization review procedures, including any prior authorization          |
| 15 | <del>procedures; and</del>  |
| 16 | (3) the procedures by which drugs will be identified as preferred on the          |
| 17 | preferred drug list, and the procedures by which drugs will be selected for prior |
| 18 | authorization or any other utilization review procedure.                          |
| 19 | (b) The Committees shall closely monitor implementation of the preferred          |
| 20 | drug list and utilization review procedures to ensure that the consumer           |

protection standards enacted pursuant to section 1999 of this title are not

| 1  | diminished as a result of implementing the preferred drug list and the             |
|----|--|
| 2  | utilization review procedures, including any unnecessary delay in access to        |
| 3  | appropriate medications. The Committees shall ensure that all affected             |
| 4  | interests, including consumers, health care providers, pharmacists, and others     |
| 5  | with pharmaceutical expertise have an opportunity to comment on the                |
| 6  | preferred drug list and procedures reviewed under this subsection.                 |
| 7  | (c) The Notwithstanding the provisions of 2 V.S.A. § 20(d), the                    |
| 8  | Commissioner of Vermont Health Access shall report annually on or before           |
| 9  | October 30 to the House Committees on Appropriations, on Health Care, and          |
| 10 | on Human Services and the Senate Committees on Appropriations and on               |
| 11 | Health and Welfare concerning the Pharmacy Best Practices and Cost Control         |
| 12 | Program and the operation of Vermont's pharmaceutical assistance programs          |
| 13 | for the most recent State fiscal year. Topics covered in the report shall include: |
| 14 | (1) issues related to drug cost and utilization;                                   |
| 15 | (2) the effect of national trends on the pharmacy program;                         |
| 16 | (3) comparisons to other states;   |
| 17 | (4) the Department's administration of Vermont's pharmaceutical                    |
| 18 | assistance programs;   |
| 19 | (5) the Department's use of prior authorization requirements for                   |
| 20 | prescription drugs; and  |

| 1  | (6) decisions made by the Department's Drug Utilization Review Board              |
|----|---|
| 2  | in relation to both drug utilization review efforts and the placement of drugs on |
| 3  | the Department's preferred drug list.   |
| 4  | (d) [Repealed.]   |
| 5  | (e)(b)(1) [Repealed.]   |
| 6  | (2) The Commissioner shall not enter into a contract with a pharmacy              |
| 7  | benefit manager unless the pharmacy benefit manager has agreed to disclose to     |
| 8  | the Commissioner the terms and the financial impact on Vermont and on             |
| 9  | Vermont beneficiaries of:   |
| 10 | * * *   |
| 11 | (3)(2) The Commissioner shall not enter into a contract with a pharmacy           |
| 12 | benefit manager who has entered into an agreement or engaged in a practice        |
| 13 | described in subdivision $(2)(1)$ of this subsection, unless the Commissioner     |
| 14 | determines that the agreement or practice furthers the financial interests of     |
| 15 | Vermont and does not adversely affect the medical interests of Vermont            |
| 16 | beneficiaries.  |
| 17 | Sec. 4. 33 V.S.A. § 2081 is amended to read:                                      |
| 18 | § 2081. RULES AND LEGISLATIVE OVERSIGHT RULEMAKING                                |
| 19 | (a) The Agency of Human Services shall adopt rules necessary to                   |
| 20 | implement and administer the provisions of this subchapter, including             |
| 21 | standards and schedules establishing coverage and exclusion of                    |

| 1  | pharmaceuticals and maximum quantities of pharmaceuticals to be dispensed,  |
|----|---|
| 2  | and to comply with the requirements of the Medicare Modernization Act. The  |
| 3  | Agency of Human Services shall submit the proposed rule to the Health Care  |
| 4  | Oversight Committee. The Health Care Oversight Committee shall review and   |
| 5  | advise on the Agency rules and policies developed under this subsection and |
| 6  | shall submit for consideration any recommendations to the joint Legislative |
| 7  | Committee on Administrative Rules.  |
| 8  | (b) DVHA shall report on the status of the pharmaceutical assistance        |
| 9  | programs established by this subchapter to the Health Care Oversight        |
| 10 | Committee.  |
| 11 | Sec. 5. EFFECTIVE DATES   |
| 12 | (a) Secs. 1 (Exchange plan premium processing; purpose) and 2 (33 V.S.A.    |
| 13 | § 1805) shall take effect on October 1, 2020.                               |
| 14 | (b) The remaining sections shall take effect on passage.                    |